Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP
NCT05669534Phase 4Recruiting
- Sponsor
- University of Connecticut
- Start
- Mar 2023
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial (16 arms), sponsored by University of Connecticut. Primary endpoints: Pre-Exposure Prophylaxis Adherence via Dried Blood Spots at 9 months, Pre-Exposure Prophylaxis Adherence via pharmacy refill data at 9 months and 1 more. Started Mar 2023; status: recruiting.
Beyond the preview
Go deeper on NCT05669534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05669534.